Compare ALVO & QFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALVO | QFIN |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | Luxembourg | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2021 | 2018 |
| Metric | ALVO | QFIN |
|---|---|---|
| Price | $6.16 | $6.70 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 13 |
| Target Price | $6.80 | ★ $14.80 |
| AVG Volume (30 Days) | 1.1M | ★ 1.7M |
| Earning Date | 11-11-2026 | 11-17-2026 |
| Dividend Yield | N/A | ★ 24.15% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.96 | N/A |
| Revenue Next Year | $17.65 | N/A |
| P/E Ratio | $18.20 | ★ $2.21 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.94 | $6.41 |
| 52 Week High | $9.05 | $30.40 |
| Indicator | ALVO | QFIN |
|---|---|---|
| Relative Strength Index (RSI) | 66.45 | 19.30 |
| Support Level | $3.15 | N/A |
| Resistance Level | N/A | $14.03 |
| Average True Range (ATR) | 0.34 | 0.28 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 75.77 | 10.95 |
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.
Qfin Holdings Inc is engaged in matching individual borrowers with credit demand to a diversified pool of financial institutions with credit to supply through a financial technology platform. It has released large-scale financial credit multimodal benchmark, building a critical bridge between credit AI research and real-world applications.